ProQR Historical Financial Ratios
| PRQR Stock | USD 3.54 0.08 2.21% |
ProQR Therapeutics is promptly reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.49, Free Cash Flow Yield of 0.13, Invested Capital of 0.0 or Operating Cash Flow Per Share of 0.28 will help investors to properly organize and evaluate ProQR Therapeutics financial condition quickly.
ProQR |
About ProQR Financial Ratios Analysis
ProQR TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ProQR Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ProQR financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ProQR Therapeutics history.
ProQR Therapeutics Financial Ratios Chart
Add Fundamental
Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from ProQR Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ProQR Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. At this time, ProQR Therapeutics' Capex To Revenue is relatively stable compared to the past year. As of 11/26/2024, POCF Ratio is likely to grow to 7.07, while Days Sales Outstanding is likely to drop 67.50.
| 2020 | 2021 | 2023 | 2024 (projected) | Payables Turnover | 9.93 | 6.32 | 0.0866 | 0.0823 | Days Of Inventory On Hand | 63.05 | 1.01 | 1.16 | 1.11 |
ProQR Therapeutics fundamentals Correlations
Click cells to compare fundamentals
ProQR Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProQR Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 94.83 | 187.6 | 333.9 | 61.32 | 22.28 | 21.16 | |
| Ptb Ratio | 3.84 | 3.01 | 3.97 | 3.78 | 3.51 | 3.68 | |
| Book Value Per Share | 2.29 | 1.13 | 1.76 | 0.91 | 0.51 | 0.49 | |
| Free Cash Flow Yield | (0.0661) | (0.12) | (0.28) | (0.0586) | 0.12 | 0.13 | |
| Operating Cash Flow Per Share | (1.07) | (0.94) | (0.41) | (0.96) | 0.27 | 0.28 | |
| Stock Based Compensation To Revenue | 0.65 | 4.71 | 4.59 | 0.71 | 0.48 | 0.45 | |
| Capex To Depreciation | 0.31 | 0.28 | 0.39 | 0.21 | 1.48 | 2.33 | |
| Pb Ratio | 3.84 | 3.01 | 3.97 | 3.78 | 3.51 | 3.68 | |
| Ev To Sales | 75.36 | 136.7 | 239.99 | 43.29 | 7.05 | 6.7 | |
| Roic | (0.54) | (0.57) | (0.36) | (0.9) | (0.7) | (0.73) | |
| Inventory Turnover | 1.09 | 343.6 | 5.79 | 360.61 | 324.55 | 340.78 | |
| Net Income Per Share | (1.38) | (0.93) | (0.96) | (0.91) | (0.35) | (0.36) | |
| Days Of Inventory On Hand | 333.64 | 1.06 | 63.05 | 1.01 | 1.16 | 1.11 | |
| Payables Turnover | 7.29 | 262.52 | 9.93 | 6.32 | 0.0866 | 0.0823 | |
| Sales General And Administrative To Revenue | 2.54 | 6.67 | 12.83 | 4.62 | 2.49 | 2.37 | |
| Research And Ddevelopement To Revenue | 5.97 | 24.05 | 31.18 | 12.6 | 3.86 | 3.67 | |
| Capex To Revenue | 0.0631 | 0.3 | 0.36 | 0.18 | 0.56 | 0.8 | |
| Cash Per Share | 2.73 | 1.51 | 2.92 | 1.32 | 1.47 | 1.39 | |
| Pocfratio | (8.25) | (3.66) | (17.38) | (3.61) | 6.73 | 7.07 | |
| Interest Coverage | (53.04) | (20.77) | (16.8) | (12.62) | (26.48) | (27.81) | |
| Capex To Operating Cash Flow | (0.0132) | (0.0196) | (0.0186) | (0.0103) | 0.17 | 0.18 | |
| Pfcf Ratio | (8.14) | (3.59) | (17.06) | (3.58) | 8.31 | 8.73 | |
| Days Payables Outstanding | 50.1 | 1.39 | 36.76 | 57.8 | 4.2K | 4.4K | |
| Income Quality | 0.77 | 1.01 | 0.42 | 1.06 | (0.78) | (0.74) | |
| Roe | (0.6) | (0.82) | (0.54) | (0.99) | (0.68) | (0.65) | |
| Ev To Operating Cash Flow | (6.01) | (2.77) | (12.49) | (2.55) | 2.13 | 2.24 | |
| Pe Ratio | (6.39) | (3.69) | (7.33) | (3.81) | (5.16) | (5.42) | |
| Return On Tangible Assets | (0.33) | (0.48) | (0.47) | (0.29) | (0.38) | (0.2) | |
| Ev To Free Cash Flow | (5.93) | (2.72) | (12.26) | (2.52) | 2.63 | 2.76 | |
| Earnings Yield | (0.16) | (0.27) | (0.14) | (0.26) | (0.19) | (0.2) | |
| Net Debt To E B I T D A | 0.56 | 0.3 | 2.31 | 1.29 | 4.12 | 4.32 | |
| Current Ratio | 10.43 | 7.77 | 6.94 | 7.32 | 3.54 | 3.36 | |
| Tangible Book Value Per Share | 2.29 | 1.13 | 1.76 | 0.91 | 0.51 | 0.49 | |
| Graham Number | 8.46 | 4.89 | 6.19 | 4.32 | 2.0 | 1.9 | |
| Shareholders Equity Per Share | 2.3 | 1.14 | 1.77 | 0.91 | 0.51 | 0.49 |
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against ProQR Stock
| 0.84 | MTEM | Molecular Templates | PairCorr |
| 0.83 | ME | 23Andme Holding | PairCorr |
| 0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.8 | TPST | Tempest Therapeutics | PairCorr |
| 0.78 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.